GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cascadian Therapeutics Inc (NAS:CASC) » Definitions » Equity-to-Asset

Cascadian Therapeutics (Cascadian Therapeutics) Equity-to-Asset : 0.90 (As of Dec. 2017)


View and export this data going back to 1991. Start your Free Trial

What is Cascadian Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cascadian Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2017 was $109.04 Mil. Cascadian Therapeutics's Total Assets for the quarter that ended in Dec. 2017 was $120.83 Mil.

The historical rank and industry rank for Cascadian Therapeutics's Equity-to-Asset or its related term are showing as below:

CASC's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.67
* Ranked among companies with meaningful Equity-to-Asset only.

Cascadian Therapeutics Equity-to-Asset Historical Data

The historical data trend for Cascadian Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cascadian Therapeutics Equity-to-Asset Chart

Cascadian Therapeutics Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.92 0.89 0.87 0.89 0.90

Cascadian Therapeutics Quarterly Data
Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.89 0.97 0.95 0.93 0.90

Competitive Comparison of Cascadian Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Cascadian Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cascadian Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cascadian Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Cascadian Therapeutics's Equity-to-Asset falls into.



Cascadian Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Cascadian Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2017 is calculated as

Equity to Asset (A: Dec. 2017 )=Total Stockholders Equity/Total Assets
=109.036/120.825
=

Cascadian Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2017 is calculated as

Equity to Asset (Q: Dec. 2017 )=Total Stockholders Equity/Total Assets
=109.036/120.825
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cascadian Therapeutics  (NAS:CASC) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Cascadian Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Cascadian Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Cascadian Therapeutics (Cascadian Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
Cascadian Therapeutics Inc is a clinical-stage biopharmaceutical company focusing in developing innovative therapeutic product candidates for the treatment of cancer. Its objective is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. The company's clinical-stage product candidate includes ONT-380, an orally active and selective small molecule HER2 inhibitor. In addition, it is also engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 kinase inhibitor and protocell technology. All the business activity of the firm is functioned through the region of United States.
Executives
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Gwen A. Fyfe director C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Steven P James director C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Julia Marie Eastland officer: CFO & CBO C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Christopher S Henney director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Robert Azelby director 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Scott Dunseth Myers director, officer: President and CEO C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Growth Equity Opportunities Iv, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea 15 Gp, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
New Enterprise Associates 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Jon Sakoda 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025

Cascadian Therapeutics (Cascadian Therapeutics) Headlines

From GuruFocus

Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics

By Kyle Ferguson Kyle Ferguson 07-11-2016